Chemical Structure (Trijardy 01)
Trijardy Xr Tablet, Extended Release
Product Images NDC 0597-0395
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Trijardy Xr (NDC 0597-0395). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Trijardy 02)
Chemical Structure (Trijardy 03)
Figure 1 (Trijardy 04)
The text provided contains a list of drugs along with their dosages and frequencies. Additionally, there are some measurements such as AUC, Cmax, and geometric mean ratio mentioned for some of the drugs. It is not clear what these measurements refer to, and the context of the list is not provided, so a specific description cannot be generated.*
Figure 2 (Trijardy 05)
This is a table of different drugs including antidiabetic drugs, oral contraceptives, and others. The table lists the amount and frequency of each drug. There are also abbreviations such as Auc, Cmax, and Geometric mean ratio with corresponding numerical values. There is no additional information available to provide more context for this table.*
Figure 3 (Trijardy 06)
Figure 4 (Trijardy 07)
This table displays the percentage of patients with an event for Placebo and All Empagliflozin at different time points (in months). There is an increasing trend of the percentage of patients with an event with time for both groups. The duration of the study was 48 months.*
Figure 5 (Trijardy 08)
Image (Trijardy 09)
Principal Display Panel (5 mg/2.5 mg/1000 mg Tablet Bottle Label)
Trijardy XR is a medication that contains empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets. Each tablet contains 5 mg of empagliflozin, 2.5 mg of linagliptin, and 1000 mg of metformin. It is dispensed with an accompanying medication guide and must not be split, crushed, dissolved, or chewed. The tablets should be stored at room temperature and protected from exposure to high humidity. The medication is manufactured by IPL Ridgefield and Lilly USA and licensed from Boehringer Ingelheim. Dosage information can be found in the prescribing information.*
Principal Display Panel (10 mg/5 mg/1000 mg Tablet Bottle Label)
Each tablet of Trijardy-XR contains 10 mg of empagliflozin, 5 mg of linagliptin, and 1000 mg of metformin hydrochloride. This medication is used for the treatment of type 2 diabetes. The dosage information can be found in the prescribing information. Trijardy-XR should not be split, crushed, dissolved, or chewed. It should be stored at controlled room temperature, protected from high humidity. This medication is dispensed in a well-closed container and should be kept out of reach of children. It is marketed by Boehringer Ingelheim Pharmaceuticals, Inc., and Eli Lilly and Company. Trijardy-XR is a trademark licensed from BI International GmbH.*
Principal Display Panel (12.5 mg/2.5 mg/1000 mg Tablet Bottle Label)
Trijardy*XR is a prescription medication that contains three active ingredients: empagliflozin, linagliptin, and metformin hydrochloride. It comes in extended-release tablets and is dispensed with an accompanying medication guide. Each tablet contains 12.5mg of empagliflozin, 2.5mg of linagliptin, and 1000mg of metformin hydrochloride. The tablets must not be split, crushed, dissolved, or chewed. The medication should be stored at a temperature between 20°C to 25°C (68°F to 77°F) and protected from high humidity. Trijardy*XR is distributed by Boehringer Ingelheim Pharmaceuticals, Inc. and marketed by BI Pharmaceuticals, Inc. and Eli Lily and Company.*
Principal Display Panel (25 mg/5 mg/1000 mg Tablet Bottle Label)
NDC 0597-0390-13 is a medication called Trijardy=XR which is available in the form of extended-release tablets. It is comprised of Empagliflozin, Linagliptin, and Metformin Hydrochloride in a specific amount. It is distributed by Boehringer Ingelheim Pharmaceuticals, Inc. and marketed by BI Pharmaceuticals, Inc. and Eli Lilly and Company. The medication guide should be accompanied while dispensing these tablets. The tablets must not be chewed or crushed, and should be stored at a temperature between 20°C to 25°C (68°F to 77°F). This medication can be dispensed only on a prescription basis.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
